This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.